English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the zaia usage as premium feature

ZAIA

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the access of premium content as premium feature

Premium Content

Zendy Tools

Zendy Open

Background  The contemporary role of prophylactic anticoagulation following extensive anterior wall  ST ‐segment myocardial infarction ( STEMI ) is unclear.    Methods and Results  We evaluated anterior  STEMI  patients with left ventricle dysfunction (left ventricular ejection fraction ≤40%) (“high risk”), categorized by prophylactic warfarin use, within a regional  STEMI . Patients with pre‐existing atrial fibrillation were excluded. The primary outcome was an adjusted (for Global Registry of Acute Coronary Events risk score) 1‐year composite of recurrent ischemia, stroke/transient ischemic attack/systemic embolism, or all‐cause death. Of the 2032  STEMI  admissions, 436 (21.5%) were high risk. After excluding 19 (4.4%) patients with definite left ventricle thrombus and 21 (4.8%) in‐hospital deaths (2 had left ventricle thrombus), prophylactic warfarin was utilized in 236/398 (59.3%) high‐risk survivors. Prescriptions were comparable across sex, but recipients were on average younger (58.5 years versus 64.0 years,  P <0.001) and lower risk (Global Registry of Acute Coronary Events risk: 163 versus 181,  P <0.001). No association on the adjusted ischemic composite (23.3% versus 25.3%, odds ratio 0.96, 95%  CI  0.60–1.55) or thromboembolic events (2.1% versus 1.2%, odds ratio 1.99, 95%  CI  0.38–10.51) was observed, but reduced 1‐year all‐cause mortality was noted (2.5% versus 8.6%, odds ratio 0.30, 95%  CI  0.11–0.81); numerically higher major bleeding was observed at 1 year (2.5% versus 1.2%, odds ratio 2.17, 95%  CI  0.43–10.96).    Conclusions  A high utilization of prophylactic warfarin occurs in anterior  STEMI  patients with left ventricle dysfunction, yet appears to provide no additional benefit on the ischemic composite. The association with lower all‐cause mortality, but higher bleeding, calls for an improved understanding of its role in high‐risk  STEMI .

journal of the american heart association

Outcomes and Prognostic Impact of Prophylactic Oral Anticoagulation in Anterior  ST ‐Segment Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction